Yucai Wang

5.8k total citations · 1 hit paper
197 papers, 3.0k citations indexed

About

Yucai Wang is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Yucai Wang has authored 197 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pathology and Forensic Medicine, 84 papers in Oncology and 63 papers in Genetics. Recurrent topics in Yucai Wang's work include Lymphoma Diagnosis and Treatment (92 papers), Chronic Lymphocytic Leukemia Research (54 papers) and CAR-T cell therapy research (37 papers). Yucai Wang is often cited by papers focused on Lymphoma Diagnosis and Treatment (92 papers), Chronic Lymphocytic Leukemia Research (54 papers) and CAR-T cell therapy research (37 papers). Yucai Wang collaborates with scholars based in United States, China and United Kingdom. Yucai Wang's co-authors include Michael Wang, Grzegorz S. Nowakowski, Narjust Duma, Jesus Vera Aguilera, Fang Yang, Stephen M. Ansell, Xiaoxiang Guan, Julian R. Molina, Xinyue Qi and Shouhao Zhou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yucai Wang

179 papers receiving 2.9k citations

Hit Papers

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibi... 2019 2026 2021 2023 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
    2019 594 citations Yucai Wang, Grzegorz S. Nowakowski et al. profile →

Peers

Yucai Wang
Andrew L. Pecora United States
Manish Sharma United States
Attilio Guarini Italy
Kai Fu United States
Mohamed E. Salama United States
David Zahrieh United States
Steven J. Lemery United States
Kim‐Anh Do United States
Jianrong Wu United States
Somak Roy United States
Andrew L. Pecora United States
Yucai Wang
Citations per year, relative to Yucai Wang Yucai Wang (= 1×) peers Andrew L. Pecora

Countries citing papers authored by Yucai Wang

Since Specialization
Citations

This map shows the geographic impact of Yucai Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yucai Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yucai Wang more than expected).

Fields of papers citing papers by Yucai Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yucai Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yucai Wang. The network helps show where Yucai Wang may publish in the future.

Co-authorship network of co-authors of Yucai Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yucai Wang. A scholar is included among the top collaborators of Yucai Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yucai Wang. Yucai Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 109(7). 2186–2195. 4 indexed citations
4.
Wang, Jacqueline, Jihao Zhou, Han W. Tun, et al.. (2024). Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study. Blood. 144(Supplement 1). 1637–1637.
5.
Tun, Aung M., Yucai Wang, Seth Maliske, et al.. (2024). Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplantation and Cellular Therapy. 30(10). 1001.e1–1001.e12. 1 indexed citations
6.
Wang, Yucai, Melissa C. Larson, Anita Kumar, et al.. (2024). Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7006–7006. 1 indexed citations
7.
Rejeski, Kai, Yucai Wang, Doris K. Hansen, et al.. (2024). Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Advances. 8(8). 1857–1868. 29 indexed citations
8.
Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520. 1 indexed citations
9.
Rejeski, Kai, Doris K. Hansen, Yucai Wang, et al.. (2023). Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality. Blood. 142(Supplement 1). 359–359. 1 indexed citations
10.
11.
Bock, Allison M., Jennifer Gile, Melissa C. Larson, et al.. (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer Journal. 13(1). 169–169. 3 indexed citations
12.
Zhang, Hengjia, et al.. (2022). Deficit mulched drip irrigation improved yield and quality while reduced water consumption of isatis indigotica in a cold and arid environment. Frontiers in Plant Science. 13. 1013131–1013131. 10 indexed citations
13.
Tun, Aung M., Arushi Khurana, Raphael Mwangi, et al.. (2022). Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances. 6(17). 5210–5221. 7 indexed citations
14.
Castellino, Alessia, Yucai Wang, Melissa C. Larson, et al.. (2021). Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances. 6(4). 1350–1360. 13 indexed citations
15.
Khurana, Arushi, Raphael Mwangi, Stephen M. Ansell, et al.. (2021). Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal. 11(7). 133–133. 6 indexed citations
16.
Kulkarni, Amit, Beibei Xu, Haitao Chu, et al.. (2020). Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer Journal. 10(3). 33–33. 26 indexed citations
17.
Wang, Yucai, Brian K. Link, Thomas E. Witzig, et al.. (2019). Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 134(16). 1289–1297. 20 indexed citations
18.
Wang, Yucai, Kerstin Wenzl, Michelle K. Manske, et al.. (2019). Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal. 9(9). 73–73. 38 indexed citations
19.
Wang, Yucai, Umar Farooq, Brian K. Link, et al.. (2018). Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood. 132(Supplement 1). 454–454. 1 indexed citations
20.
Wang, Yucai, et al.. (2010). Generation and Identification of Monoclonal Antibodies Against FNIII Domain D of Human Tenascin-C. Hybridoma. 29(1). 13–16. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew L. Pecora Breakdown of academic impact, for papers by Manish Sharma Breakdown of academic impact, for papers by Attilio Guarini Breakdown of academic impact, for papers by Kai Fu Breakdown of academic impact, for papers by Mohamed E. Salama Breakdown of academic impact, for papers by David Zahrieh Breakdown of academic impact, for papers by Steven J. Lemery Breakdown of academic impact, for papers by Kim‐Anh Do Breakdown of academic impact, for papers by Jianrong Wu Breakdown of academic impact, for papers by Somak Roy
Rankless by CCL
2026